Document:

curr_ex101.htm

EXHIBIT 10.1
  
 CONSENT AND WAIVER 
  
 This CONSENT AND WAIVER (this “Waiver”), dated as of February 25, 2021, is entered into by and between CURE Pharmaceutical Holding Corp., a Delaware corporation with offices located at 1620 Beacon Place, Oxnard, California 93033 (the “Company”), and Ionic Ventures, LLC, a California limited liability company with offices located at 3053 Fillmore Street, Suite 256, San Francisco, CA 94123 (the “Investor”). 
  
 WHEREAS, the Company and the Investor are parties to that certain Securities Purchase Agreement, dated as of October 30, 2020 (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”), pursuant to which the Investor purchased a Series A Note and a Series B Note (collectively, the “Notes”); and
  
 WHEREAS, the Company desires to issue Common Stock and/or Options to purchase Common Stock to consultants and other service providers of the Company and its Subsidiaries from time to time, and have such issuances treated as issuances of Excluded Securities under the Purchase Agreement and the Notes, and the Investor consents to, and has agreed to waive, in part, certain terms of the Purchase Agreement and the Notes such that issuances of up to 1.5 million shares of Common Stock (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events), in the aggregate, to such consultants and/or other service providers, respectively, shall hereafter be deemed to be Excluded Securities (as defined in each of the Purchase Agreement and the Notes) thereunder.
  
 NOW THEREFORE, in consideration of the mutual conditions and agreements set forth in the Transaction Documents and this Waiver, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
  
 Section 1. Definitions. Capitalized terms used in this Waiver, unless otherwise defined herein, shall have the meaning ascribed to such term in the Purchase Agreement or the Notes, as applicable.
  
 Section 2. Waiver and Consent. 
  
 (a) The Investor, as the sole Required Holder, hereby consents to the Consultant Issuances (as defined below) and, solely with respect to the Consultant Issuances and not with respect to any other Dilutive Issuance, that Section 9(e) and 4(k) of the Securities Purchase Agreement and Section 16 and 7(a) of each Note, respectively, shall each be irrevocably waived in part, solely to the extent necessary to cause the definition of “Excluded Securities” as used therein to be deemed to include the Consultant Issuances.
  
 (b) “Consultant Issuance” means an issuance, which does not otherwise constitute an issuance of Excluded Securities, by the Company of Common Stock or Options to purchase Common Stock to consultants or other service providers providing services to the Company or any of its Subsidiaries (and the subsequent issuance of Common Stock upon exercise of such Options); provided that Consultant Issuances shall not exceed, in the aggregate, 1,500,000 shares of Common Stock (as adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions that occur with respect to the Common Stock after the date of this Waiver).
   
 	 
	1
	

	 

 
 
  
 Section 3. Ratification. Except as expressly modified and superseded by this Waiver, the terms and provisions of the Purchase Agreement and the Notes are ratified and confirmed and shall continue in full force and effect. 
  
 Section 4. Disclosure of Transaction. On or before 9:30 a.m., New York time, on the first Business Day after the date of this Waiver, the Company shall disclose (including, but not limited to, filing a Current Report on Form 8-K or dissemination of a press release) all the material terms of the transactions contemplated hereby (the “Cleansing Release”). From and after dissemination of the Cleansing Release, the Company shall have disclosed all material, non-public information (if any) provided to the Investor by the Company or any of its Subsidiaries or any of their respective officers, directors, employees or agents in connection with the transactions contemplated hereby. In addition, effective upon the dissemination of the Cleansing Release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Investor or any of its affiliates, on the other hand, relating to the transactions contemplated hereby, shall terminate.
  
 Section 5. Fees. The Company shall promptly reimburse Kelley Drye & Warren, LLP (counsel to the Investor), on demand, a non-accountable amount of $5,000 for the costs and expenses incurred by it in connection with preparing and delivering this Waiver.
  
 Section 6. Incorporation by Reference. Each of Sections 9(a) (Governing Law; Jurisdiction; Jury Trial), 9(b) (Counterparts), 9(d) (Severability; Maximum Payment Amounts), 9(e) (Entire Agreement; Amendments); 9(f) (Notices); 9(g) (Successors and Assigns) 9(j) (Further Assurances) and 9(l) (Construction) of the Purchase Agreement are hereby incorporated herein by reference to refer to this Waiver, mutatis mutandis.
  
 [Signature Page Follows]
   
 	 
	2
	

	 

 
 
   
 IN WITNESS WHEREOF, the parties hereto have caused this Waiver to be duly executed under seal and delivered by their respective duly authorized officers on the date first written above.
   
 	 	Company:	
	  
	  
	  

	  
	 CURE Pharmaceutical Holding Corp.
	  

	 	 	 	 
		By:	/s/ Michael Redard	
	  
	 Name: 
	Michael Redard	 
	 	 Title: 
	CFO	 

 
 
      
 	 	 Investor:
	
	  
	  
	  

	  
	 IONIC VENTURES, LLC
	  

	 	 	 	 
		By:	/s/ Brendan O'Neil	
	  
	 Name: 
	Brendan O'Neil	 
	 	Title: 	Authorized Signatory	 

 
 
   
 	 
	3Document

EXHIBIT 10.71

TERMS OF AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT

The form of Performance Share Unit Award Agreement (the “Agreement”), filed as Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, contains blanks where the grantee's name, target number of shares, grant date, vesting date, performance measurement period, shortened performance measurement period start date, and months in term provided under the Agreement vary for each executive.

On January 25, 2021, performance share awards were granted providing certain executives the opportunity to earn common stock, the number of which is determined pursuant to, and subject to the attainment of performance goals. The performance share awards were granted with a term of 36 months and vest on January 25, 2024. The performance period start date was January 1, 2021 thereby making the performance period January 1, 2021 through December 31, 2023. The target number of shares for each executive awarded performance shares on January 25, 2021 is listed below.
						
	Executive Officer	Target number of shares
	Edward O. Handy III	8,720
	Mark K.W. Gim	4,180
	Ronald S. Ohsberg	3,250
	Kristen L. DiSanto	2,830
	James M. Hagerty	2,830
	Mary E. Noons	2,830
	Kathleen A. Ryan	2,830
	William K. Wray	2,830
	Dennis L. Algiere	2,080
	Debra A. Gormley	2,080
	Maria N. Janes	2,080Document

Exhibit 4.10

DESCRIPTION OF REGISTRANT’S SECURITIES  
REGISTERED PURSUANT TO SECTION 12 OF  
THE SECURITIES EXCHANGE ACT OF 1934 
The following is a summary description of common stock of Ekso Bionics Holdings, Inc. (the “Company” or “we,” “us” or “our”), which the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following summary does not purport to be complete and is subject to and qualified in its entirety by reference to the applicable provisions of Nevada law, our articles of incorporation, as amended (“charter”) and our bylaws (“bylaws”).  For a complete description of our common stock, we refer you to our charter and our bylaws, which are included as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2020.  The summary below is also qualified by provisions of applicable law.
DESCRIPTION OF COMMON STOCK
General
Under our charter, we are authorized to issue 141,428,571 shares of common stock, par value $0.001 per share. 
Dividends. The holders of outstanding shares of common stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times and in such amounts as the board from time to time may determine. 
Voting. Holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. There is no cumulative voting of the election of directors then standing for election. 
Pre-emptive Rights, Redemption, Conversion and Sinking Fund Provisions. The common stock is not entitled to pre-emptive rights and is not subject to conversion, redemption or sinking fund provisions. 
Liquidation Rights. Upon liquidation, dissolution or winding up of our Company, the assets legally available for distribution to stockholders are distributable ratably among the holders of the common stock after payment of liquidation preferences, if any, on any outstanding payment of other claims of creditors. Each outstanding share of common stock is duly and validly issued, fully paid and non-assessable. 
Transfers. There are no restrictions on the transfer of our common stock except such restrictions as may be imposed by applicable securities laws.
Listing
Our common stock is listed on the Nasdaq Capital Market under the symbol “EKSO.”

        1Document

Exhibit 10.30

THIRD AMENDMENT TO LEASE AGREEMENT

THIS THIRD AMENDMENT TO LEASE AGREEMENT (this “3rd Amendment”) is made as of June 16, 2020, between FPOC, LLC, a California limited liability company (hereinafter called "Landlord"), and Ekso Bionics, Inc., a Delaware corporation (hereinafter called "Tenant"), having a place of business at 1414 Harbour Way So., Suite 1201, Richmond, California 94804 (the “Premises”).

RECITALS:

A.Landlord is the owner of the office building located at 1414 Harbour Way So., Richmond, California 94804, and commonly known as The Ford Building (the “Building”).

B.Tenant occupies the Premises pursuant to a Lease dated as of November 29, 2011, as amended by a First Amendment to Lease Agreement dated as of March 28, 2012, and a Second Amendment to Lease Agreement dated as of November 5, 2016 (collectively, the “Lease”).

C.Tenant is delinquent in the payment of the Base Rent (as described in Paragraph 3 of the Second Amendment to Lease) and Tenant’s Operating Cost Share for April and May, 2020 (being $68,274.26 and $25,026.96, respectively) and desires to modify said rent payments to provide for a lump sum (being paid herewith), to amortize (for payment during 2021) certain sums, and to be provided an abatement of certain sums, all of which Landlord is prepare to accommodate and agree to, as set forth and subject to the terms and conditions set forth herein.

AGREEMENT:

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

a.Capitalized Terms; Incorporation of Recitals. Capitalized terms used but not defined in this 3rd Amendment shall have the meanings ascribed to them in the Lease. The recitals set forth above are incorporated by reference in this 3rd Amendment with the same force and effect as if repeated at length.

b.Rent Adjustment. Tenant pays herewith to Landlord the sum of Three Hundred Thousand and 00/100 Dollars ($300,000.00) (the “Lump Sum”). Said sum shall be applied as follows:

First:    To the Base Rent due for April and May, 2020 (in the amount of
$68,274.26) and to the Tenant’s Operating Cost Share for April and May, 2020 (in the amount of $25,026.96), being the combined amount of $93,301.22;

1

Second: The balance thereof (being $ $206,698.78) shall be accepted by Landlord as payment in full for the Base Rent otherwise due for the period of June 1 through December 31, 2020 (being $246,128.68, being $35,161.24 x seven months) and for the Tenant’s Operating Cost Share (paid as a monthly estimate) for the period of June 1 through December 31, 2020 (being $87,594.36, being
$12,513.48 x seven months), provided that Tenant pays monthly, timely and in full (due the same day as the payment of Base Rent) from and after January 1, 2021 and for twelve (12) monthly payments thereafter, the sum of $6,612.46 (being a total of such payments of $79,349.54 (the “Deferred Payment Amount”)). For clarity of understanding in the preceding, the parties acknowledge that the aggregate sum of Base Rent otherwise due for the period of April through December, 2020, is $314,402.94, and Tenant’s Operating Cost Share for the same period is $112,621.32, for an aggregate sum of $427,024.26. Upon application of the Lump Sum, a balance owing remains of $127,024.26. Upon payment of the Deferred Payment Amount ($79,349.54), said balance remaining would be
$47,674.72.

Provided and conditioned upon no event of default having occurred or then existing under the Lease (beyond any applicable cure period), then Landlord shall credit to Tenant, on December 31, 2020, the sum of $47,674.72 (being abated rent otherwise due under the Lease), which credit shall be an inducement. The preceding inducement is conditioned upon Tenant’s full and faithful performance of all of the terms, covenants and conditions of this Lease. In the event of default (beyond any applicable cure period) said inducement shall automatically be deemed deleted from this Lease and of no further force or effect, and any credit/abatement given or paid by Landlord shall be immediately due and payable by Tenant to Landlord.

Landlord expressly waives its right to any late fees otherwise provided for under the Lease, as to the payment delinquency for April and May, 2020. The provisions of Paragraph 5.4 of the Lease (setting forth the process for the annual accounting and reconciliation of Tenant’s Operating Cost Share) shall continue to apply and, as to calendar year 2020, Tenant’s payments thereto shall be deemed to be in the amount of $150,161.76.

Tenant’s payment obligations for Base Rent as of January 1, 2021 shall be as otherwise stated in the Lease and specifically in Paragraph 3 of the Second Amendment to Lease. Notwithstanding anything to the contrary set forth in the Lease, all payments by Tenant as of January 1, 2021 shall first be applied to the monthly payment due towards the Deferred Payment Amount, and thereafter to all other sums due under the Lease. The Lump Sum paid herewith is deemed and agreed to be “earned” immediately by Landlord, and not subject to proration or allocation to any specific or subsequent period(s) of time, and is paid in consideration of Landlord entering into this 3rd Amendment, including waiving of certain late fees and providing for the potential abatement described herein.

2

a.Continued Enforceability. The parties acknowledge and agree that the Lease remains in full force and effect, unchanged except as expressly provided for in this 3rd Amendment. This 3rd Amendment and the Lease shall be read together as one document. In the event of any conflict between the terms of this 3rd Amendment and the terms of the Lease, the terms of this 3rd Amendment shall govern.

b.Governing Law. This 3rd Amendment shall be governed by and construed and enforced in accordance with the laws of the State of California.

c.Further Modifications. This 3rd Amendment may only be modified pursuant to a written agreement signed by all of the parties hereto.

d.Entire Agreement. This 3rd Amendment and the documents described herein contain the entire agreement between the parties hereto with respect to the matters described herein and supersede all prior agreements, oral or written, between the parties hereto with respect to such matters.

e.Counterparts. This 3rd Amendment may be executed in several counterparts and all so executed shall constitute one agreement, binding upon all of the parties hereto, notwithstanding that all of the parties are not signatories to the same counterpart.

IN WITNESS WHEREOF, the parties have executed this 3rd Amendment as of the date first written above.

LANDLORD:    TENANT:
FPOC, LLC    EKSO BIONICS, INC.
A California limited liability company    A Delaware corporation

By: /s/ J.R. Orton, III
        J.R. Orton, III
        Manager
  By: /s/ John F. Glenn         
  Name: John F. Glenn    
    Title:  CFO    

By:         Name:         Title:      
3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]